Recent advances in antiretroviral drugs

Bibliography

• UNAIDS. AIDS epidemic update [online]. Available from: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf [Cited on 12 November 2009]
   Google Scholar
• Palella FJ, Delaney KM, Moorman AC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus (HIV) infection. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Pedersen C, Clumeck N, Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ 1994;308:1068-73
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
   PubMed Web of Science ®Google Scholar
• Mocroft A, Velia S, Benfield TL, Changing patterns of mortality across Europe in patients infected with HIV-1. Euro SIDA Study Group. Lancet 1998;352:1725-30
   PubMed Web of Science ®Google Scholar
• Sun J, Ma L, Yu X, Replication and drug resistant mutation of HIV-1 subtype B′ (Thailand B) variants isolated from HAART treatment individuals in China. Virol J 2009;6:201
   PubMedGoogle Scholar
• Corona A, Raimondi F. Caring for HIV-infected patients in the ICU in the highly active antiretroviral therapy era. Caries Curr HIV Res 2009;7:569-79
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7. Published 3 November 2008. [Accessed 7 November 2009]
   Google Scholar
• Richman DD, Morton SC, Wrin T, The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-401
   PubMed Web of Science ®Google Scholar
• Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23
   PubMedGoogle Scholar
• Tozzi V, Zaccarelli M, Bonfigli S, Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60
   PubMedGoogle Scholar
• Truong HM, Grant RM, McFarland W, Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-7
   PubMed Web of Science ®Google Scholar
• Drosopoulos WC, Rezende LF, Wainberg MA, Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? J Mol Med 1998;76:604-12
   PubMed Web of Science ®Google Scholar
• Keulen W, Nijhuis M, Schuurman R, Reverse transcriptase fidelity and HIV-1 variation. Science 1997;275:229-31
   PubMed Web of Science ®Google Scholar
• Spira S, Wainberg MA, Loemba H, Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003;51:229-40
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Osman H. Novel targets for anti-retroviral therapy. J Infect 2009;59:377-86
   PubMedGoogle Scholar
• Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810
   PubMed Web of Science ®Google Scholar
• Latinovic O, Kuruppu J, Davis C, Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther 2009;1:1497-510
   PubMedGoogle Scholar
• Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003;281:1-27
   PubMed Web of Science ®Google Scholar
• Hobaika Z, Zargarian L, Maroun RG, HIV-1 integrase and virus and cell DNAs: complex formation and perturbation by inhibitors of integration. Neurochem Res 2010;35:888-93
   PubMedGoogle Scholar
• McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antiviral Res 2010;85:101-18
   PubMed Web of Science ®Google Scholar
• Verheyen J, Verhofstede C, Knops E, High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 2010;24(5):669-7
   PubMedGoogle Scholar
• Maagaard A, Kvale D. Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. Scand J Infect Dis 2009;41:808-17
   PubMed Web of Science ®Google Scholar
• Balzarini J, Camarasa MJ, Perez-Perez MJ, Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J Virol 2001;75:5772-7
   PubMedGoogle Scholar
• Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J Mol Biol 2007;365:298-309
   PubMedGoogle Scholar
• Li J, Li L, Li HP, Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations. Chin Med J (Engl) 2009;122:1081-6
   PubMedGoogle Scholar
• Wirden M, Lambert-Niclot S, Marcelin AG, Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. AIDS 2009;23:95-9
   PubMed Web of Science ®Google Scholar
• Narayanasamy J, Pullagurla MR, Sharon A, Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. Antiviral Res 2007;75:198-209
   PubMed Web of Science ®Google Scholar
• Gripshover BM, Ribaudo H, Santana J, Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther 2006;11:619-23
   PubMedGoogle Scholar
• Colucci P, Pottage JC, Robison H, Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother 2009;53:646-50
   PubMedGoogle Scholar
• Hurwitz SJ, Otto MJ, Schinazi RF. Comparative pharmacokinetics of Racivir, (+/-)-beta-2′,3′-dideoxy-5- fluoro-3′-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir Chem Chemother 2005;16:117-27
   PubMedGoogle Scholar
• Cahn P, Wainberg MA. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J Antimicrob Chemother 2010;65:213-17
   PubMedGoogle Scholar
• Bacheler L, Jeffrey S, Hanna G, Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnudeoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A, Resistance profile and cross resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-8
   PubMed Web of Science ®Google Scholar
• Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 2009;31:692-704
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
   PubMed Web of Science ®Google Scholar
• Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2009;18:1035-41
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27
   PubMed Web of Science ®Google Scholar
• Adams J, Patel N, Mankaryous N, Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010;44:157-65
   PubMed Web of Science ®Google Scholar
• Djedaini M, Peraldi P, Drici MD, Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009;386:96-100
   PubMed Web of Science ®Google Scholar
• Caron M, Vigouroux C, Bastard JP, Capeau J. Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARgamma-dependent pathways. PPAR Res 2009;2009:507141
   PubMedGoogle Scholar
• Uglietti A, Novati S, Gulminetti R, Maserati R. Correlations between atazanavir C (trough) and hyperbilirubinemia: a case report. J Med Case Rep 2009;3:9307
   PubMedGoogle Scholar
• Tenore SB, Ferreira PR. The place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009;13:371-4
   PubMed Web of Science ®Google Scholar
• Raffi F, Battegay M, Rusconi S, Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-80
   PubMed Web of Science ®Google Scholar
• Arasteh K, Yeni P, Pozniak A, Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14:859-64
   PubMed Web of Science ®Google Scholar
• Arribas JR, Horban A, Gerstoft J, The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-30
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008;10:131-42
   PubMed Web of Science ®Google Scholar
• Estrada V, Fuster M. Darunavir in treatment-naive patients. The ARTEMIS study. Enferm Infecc Microbiol Clin 2008;26(Suppl 10):10-3
   PubMedGoogle Scholar
• FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009;24:106-7
   Google Scholar
• Stellbrink HJ. Raltegravir in the management of HIV-infected patients. Drug Des Dev Ther 2009;2:281-8
   PubMedGoogle Scholar
• Lennox JL, DeJesus E, Lazzarin A, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806
   PubMed Web of Science ®Google Scholar
• Shimura K, Kodama EN. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 2009;20:79-85
   PubMedGoogle Scholar
• Fransen S, Gupta S, Danovich R, Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple non overlapping genetic pathways. J Virol 2009;83:11440-6
   PubMed Web of Science ®Google Scholar
• Vandeckerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr Opin Investig Drugs 2010;11:203-12
   PubMedGoogle Scholar
• Ray S, Fatima Z, Saxena A. Drugs for AIDS. Mini Rev Med Chem 2010;10:147-61
   PubMed Web of Science ®Google Scholar
• Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet 2003;361:1577-8
   PubMedGoogle Scholar
• Lalezari JP, Henry K, O'Hearn M, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
   PubMed Web of Science ®Google Scholar
• He Y, Xiao Y, Song H, Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283:11126-34
   PubMed Web of Science ®Google Scholar
• Pan C, Lu H, Qi Z, Jiang S. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 2009;23:639-41
   PubMedGoogle Scholar
• Covens K, Megens S, Dekeersmaeker N, The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res 2010;86(3):253-60
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Maraviroc. Drugs 2007;67:2277-88
   PubMed Web of Science ®Google Scholar
• Cooper DA, Heera J, Goodrich J, Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
   PubMed Web of Science ®Google Scholar
• Fadel H, Temesgen Z. Maraviroc. Drugs Today (Barc) 2007;43:749-58
   PubMed Web of Science ®Google Scholar
• Kummerle T, Lehmann C, Hartmann P, Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opin Investig Drugs 2009;18:1773-85
   PubMed Web of Science ®Google Scholar
• Gathe J, Diaz R, Fatkenheuer G, Phase 3 Trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone [abstract 54LB]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco. 16 – 19 February 2010
   Google Scholar
• Saracino A, Monno L, Cibelli DC, Co-receptor switch during HAART is independent of virological success. J Med Virol 2009;81:2036-44
   PubMedGoogle Scholar
• Westby M, Lewis M, Whitcomb J, Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Thompson MA, Lalezari JP, Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010;201:1481-7
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Israel RJ, Lowy I, Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48(2):423-9
   PubMedGoogle Scholar
• Moyle G, DeJesus E, Boffito M, Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 2009;48:798-805
   PubMed Web of Science ®Google Scholar
• Alexander L, Zhang S, McAuliffe B, Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors. Antimicrob Agents Chemother 2009;53:4726-32
   PubMedGoogle Scholar
• Bodart V, Anastassov V, Darkes MC, Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol 2009;78:993-1000
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Jacobson J, Powderly WG, Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286-91
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Kuritzkes DR, Godofsky E, Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009;53:450-7
   PubMed Web of Science ®Google Scholar
• Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology 2010;7:36
   PubMedGoogle Scholar
• Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified? AIDS 2010;24:773-4
   PubMedGoogle Scholar
• Mathias AA, German P, Murray BP, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
   PubMed Web of Science ®Google Scholar
• UPDATE 2-Gilead Quad HIV pill succeeds in midstage study [Updated 17 Februrary 2010]. Available from: http://www.reuters.com/article/idUSN1712461120100217. [Accessed on 15 April 2010]
   Google Scholar
• Christ F, Voet A, Marchand A, First-in-class Inhibitors of LEDGF/p75-integrase Interaction and HIV replication [abstract 49]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. 16 – 19 February 2010
   Google Scholar
• Titolo S, Mercie J-F, Wardrop E, Discovery of potent HIV-1 capsid assembly inhibitors [abstract 50]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. 16 – 19 February 2010
   Google Scholar